Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients. For instance, in May 2017, NovoNodisk received Food and Drug Administration (FDA) approval for glycopegylated Rebinyn, which is used to control bleeding and bleeding management in patients diagnosed with hemophilia B.
Key manufacturers in the region focuses on developing and innovating new drugs for meeting the needs of patients, which is expected to bolster the market growth over the forecast period. For instance, in October 2012, Celgene Corporation, a U.S.-based company, received approval from the U.S. Food and Drug Administration (FDA) for Abraxane (paclitaxel protein-bound particles for injectable suspension), which is used for first-line treatment of advanced non-small cell lung cancer.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients